SMURF2 and breast cancer: Further investigation revealed that PIAS3 potentially maintained a non-invasive phenotype through Smurf2 SUMOylation in human MDA-MB-231 breast cancer cells, indicating an anti-metastatic activity of SUMOylated Smurf2 (Chandhoke et al., 2017).